Prasad’s tenure at the helm of CBER was marked by a tumultuous relationship with the biopharma industry. (iStock / Getty Images Plus) As the calendar turned from April to May, a big change came to the ...

Prasad Kalyanaraman, VP of AWS Infrastructure Services, has been named to Amazon’s senior leadership team. (Amazon Photo) Amazon added a new member to its senior leadership team Wednesday, naming AWS ...

Vinay Prasad, M.D., is out again as the chief medical and scientific officer for the U.S. Food and Drug Administration (FDA). Last July, Prasad tendered his resignation in the wake of a fiery attack ...

The revolving door at the Food and Drug Administration has pushed out another top official: Vinay Prasad, the controversial head of the agency’s vaccine and gene therapy arm, will depart in April.

The Food and Drug Administration's embattled vaccine chief, Dr. Vinay Prasad, is once again leaving the agency — the second time in less than a year that he's departed after controversial decisions ...

The controversial head of the U.S. Food and Drug Administration's vaccines and biologics unit, Dr. Vinay Prasad, will leave the agency at the end of April. FDA commissioner Dr. Marty Makary posted ...

Homeland Security Secretary Kristi Noem is out, as Donald Trump names Markwayne Mullin to replace her. Will the DHS personnel change also affect ICE policy? Plus, does the U.S. have enough air-defense ...

The Food and Drug Administration’s vaccine chief, Dr. Vinay Prasad, will depart the agency next month, an FDA spokesperson said Friday. Limited time: Save 25% on NBC News subscription Get exclusive ...

The nation’s controversial top vaccine regulator is leaving his job at the end of April, federal health officials said Friday. Vinay Prasad had begun his role leading vaccines and complex treatments ...

Dr. Vinay Prasad drew criticism for overriding career scientists and rejecting drugs by companies seeking agency approval. By Christina Jewett Dr. Vinay Prasad, a polarizing figure at the Food and ...

Successor to be named before Prasad's departure Prasad had received criticism for his division's handling of rare disease treatments Prasad to return to UCSF March 6 (Reuters) - The controversial head ...

Vinay Prasad's signature appeared on a letter telling Moderna that the agency was refusing to review the biotech’s application for a new mRNA-based flu vaccine, a decision that was later reversed.